AXA : The decline remains the most likely outcome below the resistance
SELL
Conditionne
Stop-loss triggered
Entry price | Target | Stop-loss | Potential |
---|
€23.5 |
€22.4 |
€24 |
+4.68% |
---|
As long as the stock price has not broken through the resistance level at 23.91 EUR, investors should expect the price to decline with the short term support at 23.17 EUR as the main target.
Strengths● The stock, which is currently worth 2019 to 0.44 times its sales, is clearly overvalued in comparison with peers.
● The company's attractive earnings multiples are brought to light by a P/E ratio at 10.54 for the current year.
● This company will be of major interest to investors in search of a high dividend stock.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● Within the weekly time frame the stock shows a bullish technical configuration above the support level at 20.87 EUR
Weaknesses● The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
● According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
● The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
● For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.